Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 24;10(6):1224.
doi: 10.3390/biomedicines10061224.

Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection

Affiliations
Review

Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection

Ilaria Montali et al. Biomedicines. .

Abstract

Current treatment for chronic HBV infection is mainly based on nucleos(t)ide analogues, that in most cases need to be administered for a patient's lifetime. There is therefore a pressing need to develop new therapeutic strategies to shorten antiviral treatments. A severe dysfunction of virus-specific T cell responses contributes to virus persistence; hence, immune-modulation to reconstitute an efficient host antiviral response is considered a potential approach for HBV cure. In this perspective, a detailed understanding of the different causes of T cell exhaustion is essential for the design of successful functional T cell correction strategies. Among many different mechanisms which are widely believed to play a role in T cell dysfunction, persistent T cell exposure to high antigen burden, in particular HBsAg, is expected to influence T cell differentiation and function. Definitive evidence of the possibility to improve anti-viral T cell functions by antigen decline is, however, still lacking. This review aims at recapitulating what we have learned so far on the complex T cell-viral antigen interplay in chronic HBV infection.

Keywords: HBsAg; T cells; antigen load; chronic HBV infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of HBsAg and HBcrAg production from the HBV-infected hepatocyte. Created with: BioRender.com (accessed on 20 May 2022).

Similar articles

Cited by

References

    1. McLane L.M., Abdel-Hakeem M.S., Wherry E.J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 2019;37:457–495. doi: 10.1146/annurev-immunol-041015-055318. - DOI - PubMed
    1. Fisicaro P., Barili V., Rossi M., Montali I., Vecchi A., Acerbi G., Laccabue D., Zecca A., Penna A., Missale G., et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front. Immunol. 2020;11:849. doi: 10.3389/fimmu.2020.00849. - DOI - PMC - PubMed
    1. Rydell G.E., Prakash K., Norder H., Lindh M. Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro. Virology. 2017;509:67–70. doi: 10.1016/j.virol.2017.05.017. - DOI - PubMed
    1. Iannacone M., Guidotti L.G. Immunobiology and pathogenesis of hepatitis B virus infection. Nat. Rev. Immunol. 2022;22:19–32. doi: 10.1038/s41577-021-00549-4. - DOI - PubMed
    1. Fanning G.C., Zoulim F., Hou J., Bertoletti A. Author correction: Therapeutic STRATEGIES for hepatitis B virus infection: Towards a cure. Nat. Rev. Drug Discov. 2020;19:291. doi: 10.1038/s41573-019-0057-9. - DOI - PubMed

Grants and funding

This work was supported by a grant from Emilia-Romagna Region, Italy (Programma di Ricerca Regione-Università 2010–2012; PRUa1RI-2012-006), by a grant from the Italian Ministry of Health (Ricerca Finalizzata RF 2013-02359333) and by a PRIN (Progetti di Ricerca di Rilevante Interesse Nazionale) grant (2017MPCWPY_002), Ministry of University and Research.

LinkOut - more resources